NITROFURANTOIN SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C8H5N4O5.Na
Molecular Weight	260.1389
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-][N+](=O)C1=CC=C(O1)\C=N\N2CC(=O)[N-]C2=O

InChI

InChIKey=AFDJQFFKYDCYIG-JSGFVSQVSA-M

InChI=1S/C8H6N4O5.Na/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16;/h1-3H,4H2,(H,10,13,14);/q;+1/p-1/b9-3+;

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/009175s036lbl.pdf

Furadantin (nitrofurantoin), a synthetic chemical, is a stable, yellow, crystalline compound. Furadantin is an antibacterial agent for specific urinary tract infections. Orally administered Furadantin is readily absorbed and rapidly excreted in urine. Blood concentrations at therapeutic dosage are usually low. Unlike many drugs, the presence of food or agents delaying gastric emptying can increase the bioavailability of Furadantin, presumably by allowing better dissolution in gastric juices. Nitrofurantoin is active against some gram positive organisms such as S. aureus, S. epidermidis, S. saprophyticus, Enterococcus faecalis, S. agalactiae, group D streptococci, viridians streptococci and Corynebacterium. Its spectrum of activity against gram negative organisms includes E. coli, Enterobacter, Neisseria, Salmonella and Shigella. It may be used as an alternative to trimethoprim/sulfamethoxazole for treating urinary tract infections though it may be less effective at eradicating vaginal bacteria. May also be used in females as prophylaxis against recurrent cystitis related to coitus. Nitrofurantoin is highly stable to the development of bacterial resistance, a property thought to be due to its multiplicity of mechanisms of action. Nitrofurantoin is activated by bacterial flavoproteins (nitrofuran reductase) to active reduced reactive intermediates that are thought to modulate and damage ribosomal proteins or other macromolecules, especially DNA, causing inhibition of DNA, RNA, protein, and cell wall synthesis. The overall effect is inhibition of bacterial growth or cell death.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Probable pyruvate-flavodoxin oxidoreductase 3 Target ID: P52647 Gene ID: 946587.0 Gene Symbol: ydbK Target Organism: Escherichia coli (strain K12) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12069963	Substrate 661
DNA 278 Target ID: CHEMBL2364041 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/009175s036lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Urinary tract infections 205 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/009175s036lbl.pdf	Curative		Approved 8429	FURADANTIN Approved Use Nitrofurantoin macrocrystals is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals and other antibacterial drugs, nitrofurantoin macrocrystals should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin macrocrystals are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin macrocrystals, other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin macrocrystals, lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. Launch Date 1953

C_max

Value	Dose	Co-administered	Analyte	Population
0.326 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30859184	50 mg 4 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NITROFURANTOIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
0.69 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30859184	100 mg 3 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NITROFURANTOIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.43 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30859184	50 mg 4 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NITROFURANTOIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
6.49 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30859184	100 mg 3 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NITROFURANTOIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30859184	50 mg 4 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NITROFURANTOIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
1.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30859184	100 mg 3 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		NITROFURANTOIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7085535	unknown, unknown		NITROFURANTOIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16718946/	healthy, 50 years n = 1 Health Status: healthy Age Group: 50 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16718946/	Disc. AE: Pneumonia... AEs leading to discontinuation/dose reduction: Pneumonia Sources: https://pubmed.ncbi.nlm.nih.gov/16718946/
125 mg multiple, oral (mean) Recommended Dose: 125 mg Route: oral Route: multiple Dose: 125 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5700010/	unhealthy, 62-75 years n = 5 Health Status: unhealthy Condition: urinary infections Age Group: 62-75 years Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/5700010/	Disc. AE: Interstitial pneumonitis... AEs leading to discontinuation/dose reduction: Interstitial pneumonitis Sources: https://pubmed.ncbi.nlm.nih.gov/5700010/
50 mg 2 times / day multiple, oral Studied dose Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7019458/	unhealthy, mean age 31.3 years n = 48 Health Status: unhealthy Condition: urinary infections Age Group: mean age 31.3 years Sex: F Population Size: 48 Sources: https://pubmed.ncbi.nlm.nih.gov/7019458/	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (28%) Sources: https://pubmed.ncbi.nlm.nih.gov/7019458/

AEs

AE	Significance	Dose	Population
Pneumonia	Disc. AE	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16718946/	healthy, 50 years n = 1 Health Status: healthy Age Group: 50 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/16718946/
Interstitial pneumonitis	Disc. AE	125 mg multiple, oral (mean) Recommended Dose: 125 mg Route: oral Route: multiple Dose: 125 mg Sources: https://pubmed.ncbi.nlm.nih.gov/5700010/	unhealthy, 62-75 years n = 5 Health Status: unhealthy Condition: urinary infections Age Group: 62-75 years Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/5700010/
Nausea	28% Disc. AE	50 mg 2 times / day multiple, oral Studied dose Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7019458/	unhealthy, mean age 31.3 years n = 48 Health Status: unhealthy Condition: urinary infections Age Group: mean age 31.3 years Sex: F Population Size: 48 Sources: https://pubmed.ncbi.nlm.nih.gov/7019458/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:71415	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71415
MolPort	MolPort-001-018-217	https://www.molport.com/shop/molecule-link/MolPort-001-018-217
ZINC	ZINC000003875368	http://zinc15.docking.org/substances/ZINC000003875368
eMolecules	886566	https://www.emolecules.com/cgi-bin/more?vid=886566

PubMed

Title	Date	PubMed
[Toxic polyneuritis in a female patient with chronic pyelonephritis after long-term treatment with nitrofurantoin].	1966 Dec 8	5980645
Electrodiagnostic study of a patient with peripheral neuropathy after nitrofurantoin therapy.	1967 Apr	4290180
[Neurotoxicity of nitrofurantoin: a case of polyneuritis and acute confusional psychosis].	1968 Apr 15	5734898
[Nitrofurantoin polyneuritis].	1968 Feb	5185289
[Nil nocere. Severe polyneuropathy during nitrofurantoin therapy of renal insufficiency].	1968 Mar 14	5682390
[Apropos of a new case of polyneuritis due to nitrofurantoin].	1968 Oct 20	5742624
[Peculiarities of nitrofurantoin polyneuropathy].	1971 Apr 30	5574121
Furadantin neuropathy.	1971 Aug	4331903
[A case of curable hepatonephritis induced by prolonged treatment with nitrofurantoin].	1972 Jan 8	5010743
[Characteristics of nitrofurantoin-induced polyneuropathy].	1973	4727524
Nitrofurantoin polyneuropathy.	1973 May	4349239
Cerebellar toxic effects from nitrofurantoin.	1973 Sep	4360418
Letter: Benign intracranial hypertension associated with nitrofurantoin therapy.	1974 Dec 28	4441887
[Tetraplegia after nitrofurantoin treatment (author's transl)].	1974 May 24	4210548
Acute pulmonary reaction to nitrofurantoin.	1974 Sep	4428461
Trigeminal neuralgia induced by nitrofurantoin treatment.	1977 Aug 18	72798
The clinical significant of cystitis cystica in girls: results of a prospective study.	1978 May	660739
Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases.	1979	482863
Nitrofurantoin-induced chronic active hepatitis.	1980 Jan	7350873
[Protection against experimental neuritis caused by nitrofurantoin].	1980 Mar	7459038
Adverse reactions to nitrofurantoin. Analysis of 921 reports.	1980 Nov	7435512
Nitrofurantoin-induced granulomatous hepatitis.	1981 Aug	7269024
Lateral rectus muscle palsy associated with nitrofurantoin (Macrodantin).	1982 Dec	7180920
Activation of misonidazole by rat liver microsomes and purified NADPH-cytochrome c reductase.	1982 Feb 15	6802140
Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships.	1982 Mar-Apr	7107385
The effect of nitrofurantoin on bladder tumor cell lines: in vitro growth and implantation in the cauterized mouse bladder.	1985 Dec	4057424
[Chronic active hepatitis caused by nitrofurantoin: a case report].	1985 Jan 26	3969597
Seventh-nerve palsy and hepatitis associated with nitrofurantoin.	1986 Dec	3804357
Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome.	1987 Oct	3501698
[Toxic pulmonary and neuronal reactions to nitrofurantoin].	1990 Jan-Mar	2223723
Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs.	1991 Apr	1901343
[Unwanted side effects of antibacterials--a diagnostic challenge].	2008	19097002
Drug-induced interstitial pneumonia.	2008 Apr	18516814
N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk.	2008 Dec	18799806
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.	2008 Dec	18493746
Nitrofurantoin-induced peripheral neuropathy: a lesson to be re-learnt.	2008 Jan-Mar	18310854
Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity.	2008 Mar 15	18206659
Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice.	2009	19732493
DRESS syndrome caused by nitrofurantoin.	2009 Apr	19581659
Acute kidney injury, hepatitis, and CPK elevation associated with nitrofurantoin therapy.	2009 Feb	19214031
Nitroreductive metabolic activation of some carcinogenic nitro heterocyclic food contaminants in rat mammary tissue cellular fractions.	2009 Jan	19017535
Knocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretion.	2009 Jan-Feb	19105722
Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening.	2009 Jul	19525487
Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.	2009 Nov	19884587
Identification of genomic biomarkers for concurrent diagnosis of drug-induced renal tubular injury using a large-scale toxicogenomics database.	2009 Nov 9	19761811
Milk secretion of nitrofurantoin, as a specific BCRP/ABCG2 substrate, in assaf sheep: modulation by isoflavones.	2009 Oct	19754918
Nitrofurantoin-induced acute liver damage in pregnancy.	2009 Sep	19789166
Acute renal failure from nitrofurantoin-induced acute granulomatous interstitial nephritis.	2010 Jan	19828642
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.	2014 Jan	24085192
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

Adults: 50-100 mg four times a day -- the lower dosage level is recommended for uncomplicated urinary tract infections. Pediatric Patients: 5-7 mg/kg of body weight per 24 hours, given in four divided doses (contraindicated under one month of age).

Route of Administration: Oral

In Vitro Use Guide

In vitro nitrofurantoin has the best sensitivity in community-acquired urinary tract infections (UTIs). Nitrofurantoin has showed a low MIC distribution and high sensitivity percentage (93.3%)

Name

Type

Language

NITROFURANTOIN SODIUM

Common Name

English

Nitrofurantoin sodium [WHO-DD]

Common Name

English

IVADANTIN

Brand Name

English

NITROFURANTOIN SODIUM [ORANGE BOOK]

Common Name

English

SODIUM NITROFURANTOIN

Common Name

English

1-((5-NITROFURFURYLIDENE)AMINO)HYDANTOIN, SODIUM SALT

Common Name

English

2,4-IMIDAZOLIDINEDIONE, 1-(((5-NITRO-2-FURANYL)METHYLENE)AMINO)-, SODIUM SALT

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C255